GREAT注册研究中血管内动脉瘤修复术后五年动脉瘤囊演变:倾向性匹配对照对糖尿病患者的洞察
基于GREAT国际前瞻性注册研究,纳入2014至2016年接受GORE EXCLUDER腔内移植物择期EVAR的肾下腹主动脉瘤患者,比较糖尿病与非糖尿病(1:2倾向性匹配)患者五年囊回归率及结局。糖尿病组五年全因死亡率较高(36.3% vs 30.5%;HR 1.30,95%CI 1.07-1.58;p=.001),囊回归率(≥5 mm)无显著差异(70.0% vs 73.1%;HR 0.88,95%CI 0.75-1.04;p=.131)。
要点
- 糖尿病与非糖尿病EVAR术后五年囊回归率无显著差异(70.0% vs 73.1%;HR 0.88,95%CI 0.75-1.04;p=.131)。
- 糖尿病组五年全因死亡率较高(36.3% vs 30.5%;HR 1.30,95%CI 1.07-1.58;p=.001)。
- 1A型内漏、移植物相关再干预、MACE及动脉瘤相关死亡率两组无显著差异。
核心结论
- 糖尿病与腹主动脉瘤之间的矛盾关系似乎未导致EVAR术后囊回归率的差异。
- 即使控制其他合并症,接受EVAR的糖尿病患者五年死亡率可能更高。
研究设计与样本
- 国际前瞻性注册研究(欧洲、美国、巴西、澳大利亚和新西兰),纳入2014至2016年接受GORE EXCLUDER腔内移植物择期EVAR的肾下腹主动脉瘤且有完整五年影像随访的患者。
- 排除急诊手术、辅助近端手术以及炎性和感染性病因。
- 共纳入2 888例患者(86.1%男性;平均年龄73.5±8岁),其中545例(18.9%)有糖尿病。
- 采用倾向性评分以1:2匹配选择年龄和合并症相似的无糖尿病对照组。
主要发现
- 糖尿病组高血压(89.2% vs 78.4%)、血脂异常(76.0% vs 60.7%)、冠心病(52.3% vs 37.9%)和慢性肾功能不全(20.9% vs 14.0%)发生率更高(均p<.001)。
- 术前平均腹主动脉瘤直径58.1±10 mm。
- EVAR术后五年,1A型内漏率1.1%(糖尿病0.6% vs 非糖尿病1.2%),移植物相关再干预率7.3%(6.2% vs 7.6%),主要不良心血管事件率1.4%(1.1% vs 1.5%),动脉瘤相关死亡率1.0%(0.6% vs 1.2%),组间无统计学显著差异。
- 糖尿病组五年总死亡率较高(36.3% vs 30.5%;HR 1.30,95%CI 1.07-1.58;p=.001)。
- 囊回归率(≥5 mm)糖尿病组70.0% vs 非糖尿病组73.1%(HR 0.88,95%CI 0.75-1.04;p=.131),无统计学显著差异;排除超出使用说明书范围的患者后(p=.61)及排除1、2或3型内漏患者后(p=.39),差异仍无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess differences in the five year abdominal aortic aneurysm (AAA) sac regression rate after endovascular aneurysm repair (EVAR) in patients with and without diabetes mellitus (DM). METHODS: An international prospective registry (Europe, USA, Brazil, Australia, and New Zealand) of patients treated with the GORE EXCLUDER endograft. All scheduled EVARs for infrarenal AAA between 2014 and 2016 with complete five year imaging follow up were included. Emergency procedures, ancillary proximal procedures, and inflammatory and infectious aetiologies were excluded. Descriptive and inferential statistics, and Cox proportional hazards survival models were used. A control group of patients without DM with similar age and comorbidities was selected using propensity scores, matched in a 1:2 scheme. RESULTS: A total of 2 888 patients (86.1% male; mean age 73.5 ± 8 years) was included, of whom 545 (18.9%) had DM. Patients with DM had higher rates of hypertension (89.2% vs. 78.4%), dyslipidaemia (76.0% vs. 60.7%), coronary artery disease (52.3% vs. 37.9%), and chronic renal impairment (20.9% vs. 14.0%) (all p < .001). The mean pre-procedural AAA diameter was 58.1 ± 10 mm. Five years post-EVAR, the type 1A endoleak rate was 1.1% (0.6% DM vs. 1.2% non-DM), the endograft related re-intervention rate was 7.3% (6.2% vs. 7.6%), the major adverse cardiovascular event (MACE) rate was 1.4% (1.1% vs. 1.5%), and aortic related mortality rate was 1.0% (0.6% vs. 1.2%), without statistically significant differences between groups. The overall five year mortality rate was higher in diabetics (36.3% vs. 30.5%; hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.07 - 1.58; p = .001). No statistically significant differences were found in sac regression rate (≥ 5 mm) between diabetics and non-diabetics 70.0% vs. 73.1%; HR 0.88, 95% CI 0.75-1.04; p = .131. These differences remained statistically non-significant after excluding patients performed out of instructions for use (p = .61) and patients with types 1, 2 or 3 endoleaks (p = .39). CONCLUSION: The paradoxical relationship between DM and AAA does not appear to result in differences in post-EVAR sac regression rates. However, even when controlling for other comorbidities, patients with DM undergoing EVAR may have a higher five year mortality rate.
引用
- Álvarez Marcos F, Llaneza Coto JM, Camblor Santervás LA, et al. Five Year Post-Endovascular Aneurysm Repair Aneurysm Sac Evolution in the GREAT Registry: an Insight in Diabetics Using Propensity Matched Controls. Eur J Vasc Endovasc Surg. 2023. PMID: 37898359. doi:10.1016/j.ejvs.2023.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。